Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

[1]  J. McQuade,et al.  Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results , 2023, Nature Medicine.

[2]  N. Lin,et al.  Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan , 2023, npj Breast Cancer.

[3]  W. Gradishar,et al.  A Phase I/II Study of Intrathecal Trastuzumab in HER-2 Positive Cancer with Leptomeningeal Metastases: Safety, Efficacy, and Cerebrospinal Fluid Pharmacokinetics. , 2022, Neuro-oncology.

[4]  T. Szekeres,et al.  Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial , 2022, Nature Medicine.

[5]  K. Flaherty,et al.  Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors , 2022, JCO precision oncology.

[6]  S. Vacher,et al.  Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis. , 2022, Neuro-oncology.

[7]  M. Kris,et al.  Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Dieci,et al.  Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort , 2022, International journal of cancer.

[9]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[10]  S. Servitja,et al.  Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial , 2022, Neuro-oncology.

[11]  B. Czerniecki,et al.  Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease , 2022, Journal of Neuro-Oncology.

[12]  OUP accepted manuscript , 2022, Neuro-Oncology.

[13]  A. Giobbie-Hurder,et al.  Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis , 2021, Nature Communications.

[14]  P. Jänne,et al.  Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. , 2021, The New England journal of medicine.

[15]  P. Steeg.  The blood–tumour barrier in cancer biology and therapy , 2021, Nature Reviews Clinical Oncology.

[16]  M. Gutiérrez,et al.  Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration , 2021, Clinical pharmacology and therapeutics.

[17]  P. Siegel,et al.  The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers , 2021, Cancers.

[18]  C. Anders,et al.  HER2‐positive breast cancer brain metastasis: A new and exciting landscape , 2020, Cancer reports.

[19]  Brian L. Shaw,et al.  Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis , 2020, Nature Medicine.

[20]  R. Greil,et al.  Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. , 2019, The New England journal of medicine.

[21]  P. Wen,et al.  The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. , 2019, Neuro-oncology.

[22]  L. Norton,et al.  Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases , 2019, Clinical Cancer Research.

[23]  K. Hoang-Xuan,et al.  Intrathecal Trastuzumab as a Potential Cause of Drug-Induced Aseptic Meningitis , 2019, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[24]  E. Winer,et al.  TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Taillibert,et al.  Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. , 2018, European journal of cancer.

[26]  M. Murad,et al.  Methodological quality and synthesis of case series and case reports , 2018, BMJ Evidence-Based Medicine.

[27]  A. Seidman,et al.  Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis , 2017, Clinical breast cancer.

[28]  P. Mead,et al.  Ommaya reservoir infections: a 16-year retrospective analysis. , 2014, The Journal of infection.

[29]  D. Suki,et al.  Ommaya reservoir-related infections: clinical manifestations and treatment outcomes. , 2014, The Journal of infection.

[30]  G. Yaghmour,et al.  Drug-Induced Aseptic Meningitis Associated With Intrathecal Trastuzumab , 2014, The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians.

[31]  S. Taillibert,et al.  A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer , 2013, Journal of Neuro-Oncology.

[32]  J. Bischoff.  Multicentric, open-label, single-arm phase II study with oral lapatinib in combination with oral capecitabine plus intrathecally administered liposomal cytarabine for the treatment of meningeal metastases (NM) in HER2-positive breast cancer patients. , 2010 .

[33]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[34]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[35]  N. Harbeck,et al.  Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.

[36]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.